MediWound Receives Additional $9M From BARDA For NexoBrid FDA Application ResubmissionBenzinga • 02/10/22
MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment ProtocolGlobeNewsWire • 02/10/22
MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic WoundsGlobeNewsWire • 01/24/22
MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal WoundsGlobeNewsWire • 12/20/21
MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design StudyGlobeNewsWire • 12/06/21
MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/16/21
MediWound to Report Third Quarter 2021 Financial Results and Host a Conference Call and Webcast on November 16, 2021GlobeNewsWire • 11/04/21
Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 11/02/21
MediWound Announces Peer-Reviewed Publication of EscharEx In-Vivo Head-to-Head Comparator Study in the Journal of Wound CareGlobeNewsWire • 10/04/21
Mediwound Ltd (MDWD) CEO Sharon Malka on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/10/21
MediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021GlobeNewsWire • 08/02/21
Will MediWound (MDWD) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 07/29/21
MediWound Starts Testing MW005 In Two Mid-Stage Trials In Patients With Non-Melanoma Skin CancerBenzinga • 07/26/21
MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell CarcinomaGlobeNewsWire • 07/26/21
MediWound's NexoBrid Shows Significant Beneficial Impact On Pediatric Burn PatientsBenzinga • 07/20/21